← Back to Clinical Trials
Recruiting Phase 1 NCT06917742

A Study of CPTX2309 in Healthy Participants

Trial Parameters

Condition Healthy Volunteers
Sponsor Capstan Therapeutics
Study Type INTERVENTIONAL
Phase Phase 1
Enrollment 38
Sex ALL
Min Age 18 Years
Max Age 55 Years
Start Date 2025-04-09
Completion 2026-02
Interventions
CPTX2309CPTX2309

Brief Summary

The purpose of this study is to assess the safety and tolerability of CPTX2309 in healthy adult participants.

Eligibility Criteria

Inclusion Criteria: * Male and female participants who are healthy as determined by the investigator based on review of medical history, physical examination, and clinical laboratory tests obtained during the screening period. * Participant is willing and able to adhere to the study visit schedule and other protocol requirements. Exclusion Criteria: * Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, or clinical laboratory tests beyond what is consistent with a healthy population in the region in which the study is conducted. * Use of any investigational medical device or investigational drug within 30 days or 5 half-lives of the investigational drug (whichever is longer) prior to the first administration of CPTX2309. * Note: Other protocol-defined inclusion/exclusion criteria apply

Related Trials